Article Text

Download PDFPDF
Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis
  1. Takayoshi Morita1,
  2. Kosuke Fujimoto1,2,3,
  3. Yoshihito Shima1,
  4. Atsushi Ogata1,4,
  5. Atsushi Kumanogoh1
  1. 1 Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
  2. 2 Department of Mucosal Immunology, School of Medicine, Chiba University, Japan
  3. 3 Division of Innate Immune Regulation, Institute of Medical Science, International Research and Development Center for Mucosal Vaccines, The University of Tokyo, Japan
  4. 4 Division of Allergy, Rheumatology and Connective Tissue Disease, NTT West Osaka Hospital, Osaka, Japan
  1. Correspondence to Dr Atsushi Ogata, Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan;{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Clowse et al 1 have reported minimal to no transfer of certolizumab pegol (CZP) into breast milk, and their findings have supported the continuation of CZP treatment during breast milk feeding. Rheumatoid arthritis (RA) often develops in women of childbearing age. It is generally difficult to treat these patients with methotrexate, which is the anchor drug for RA. Therefore, biologics, such as tumour necrosis factor (TNF) inhibitors, are often considered for active RA during pregnancy. However, the biologics cross the placenta from mother to fetus and transfer into breast milk during lactation. Although a meta-analysis report indicated that anti-TNF-α therapy did not increase the risks, such as congenital malformation or abortion during pregnancy, in patients with inflammatory …

View Full Text


  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval The ethics committee approval was obtained from our hospital’s ethics committee (Medical Center for Translational and Clinical Research) (authorisation code: 11122-2).

  • Provenance and peer review Not commissioned; internally peer reviewed.